Core Viewpoint - PwC announced its mid-year results for 2025, showing a revenue increase driven by strong sales in blood purification and the introduction of revenue from regenerative medical biomaterials, despite a decline in infusion device sales [1] Financial Performance - Revenue reached approximately 414 million HKD, representing a year-on-year increase of 22.4% [1] - Profit attributable to shareholders was about 66 million HKD, reflecting a year-on-year decrease of 6.0% [1] - Earnings per share were reported at 4.44 HKD, with an interim dividend of 4.4 HKD per share [1] Business Segments - The growth in revenue was primarily attributed to robust sales in the blood purification business [1] - The regenerative medical biomaterials segment recorded its first revenue, contributing to overall growth [1] - The decline in sales from the infusion device business partially offset the revenue gains from other segments [1] Profitability Factors - The decrease in net profit was mainly due to reduced operating profit and financial income [1]
普华和顺公布中期业绩 公司拥有人应占溢利约6600万元 同比下降6.0%